Research programme: respiratory tract disorders therapeutics - Allinaire Therapeutics

Drug Profile

Research programme: respiratory tract disorders therapeutics - Allinaire Therapeutics

Alternative Names: Antibody therapeutics - Allinaire Therapeutics; Pulmonary diseases therapeutics - Allinaire Therapeutics

Latest Information Update: 06 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indiana University School of Medicine
  • Class Antibodies
  • Mechanism of Action Immunomodulators; Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Chronic obstructive pulmonary disease; Respiratory tract disorders

Most Recent Events

  • 06 Mar 2017 Research programme: respiratory tract disorders therapeutics - Allinaire Therapeutics is available for licensing as of 06 Mar 2017. http://www.allinaire.com/partners/
  • 26 Jan 2017 Early research in Chronic obstructive pulmonary disease in USA (unspecified route)
  • 26 Jan 2017 Early research in Respiratory tract disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top